X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ITM-31 is a carbonic anhydrase (CA) XII-specific antibody Fab fragment, which is currently being evaluated for the treatment of glioblastoma.
Lead Product(s): Lu-177 labeled 6A10-Fab-fragments
Therapeutic Area: Oncology Product Name: ITM-31
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Helmholtz Zentrum München
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
Through collaboration, ITM will supply its medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu) for Alpha-9's Lutetium-based candidates for the treatment of cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alpha-9 Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 30, 2024
Details:
Under the agreement, Merck will supply ITM with its first-in-class folate precursors for radiolabeling, which ITM will use to advance the clinical and potential future commercial development of its folate receptor-targeting radiopharmaceutical pipeline, including ITM-52.
Lead Product(s): ITM-52
Therapeutic Area: Oncology Product Name: ITM-52
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2023
Details:
The expanded agreement broadens the supply of ITM’s n.c.a. 177Lu to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline, including 177Lu-PNT2002 for prostate cancer.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 31, 2023
Details:
The net financing will support the development of ITM’s broad Targeted Radionuclide Therapies oncology pipeline and enhance phase III clinical development for its lead pipeline candidate, ITM-11 (n.c.a. 177Lu-edotreotide) in gastroenteropancreatic neuroendocrine tumors.
Lead Product(s): n.c.a. 177Lu-Edotreotide,Everolimus
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Temasek
Deal Size: $272.7 million Upfront Cash: Undisclosed
Deal Type: Financing June 05, 2023
Details:
Under the agreement, the partners will combine their respective technologies and expertise in the production of terbium-161 including clinical and commercial use in Targeted Radionuclide Therapy (TRT) for the treatment of cancer.
Lead Product(s): Terbium-161
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Paul Scherrer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 27, 2023
Details:
ITM-31 targets a specific protein (antigen) called CA XII, which is highly expressed on the cell surface of glioblastoma cells and destroys them while sparing the healthy tissues. It comprises a CA XII antibody Fab fragment coupled with the radioisotope 177Lu.
Lead Product(s): ITM-31
Therapeutic Area: Oncology Product Name: ITM-31
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: University Hospital Muenster
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
ITM-11 consists of two components: the medical radioisotope non-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors.
Lead Product(s): Lutetium-177-edotreotide
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Under the terms of the license agreement, ITM will hold exclusive rights to the compound ITM-31 as well as the rights to related patents and know-how for the manufacturing and use of ITM-31.
Lead Product(s): ITM-31
Therapeutic Area: Oncology Product Name: ITM-31
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Helmholtz Zentrum München
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 19, 2022
Details:
The collaboration between BAMF and ITM aims to leverage the respective strengths of both organizations to provide novel treatment options using radioisotopes that potentially improve clinical outcomes and quality of life for patients living with cancer.
Lead Product(s): Radioisotopes-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: BAMF
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
